CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Andros Pharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Andros Pharmaceuticals Co Ltd
Hsinchu Biomedical Science Park
6F, No.22, Section 2, Shengyi Road
Phone: +886 36581866p:+886 36581866 ZHUBEI, 302  Taiwan Ticker: 69176917
Business Summary
Andros Pharmaceuticals Co Ltd is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of novel drug delivery systems and liposome formulation-related products. The products are focused on topical drugs and are developed with a focus on pain-related indications. The Company is mainly engaged in the authorization of product technology transfer, as well as the manufacture and sales of niche generic drugs and high-end skin care products. Niche generic drugs and high-end skin care products include LALP Cream, which is used for anesthesia before minor skin surgery and laser treatment; iMinos Solution, which is used for the treatment of androgenetic alopecia; and deoxyribonucleic acid (DNA) repair enzyme liposome (LipoT4N5), which has anti-wrinkle, anti-sun and anti-aging effects. The products are mainly sold in Hong Kong and Taiwan.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Corporate Governance Officer BingquanChen 8/12/2024 8/12/2024
Director MingyiChen 6/19/2023
Director MingwenLi
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 44,772,000 (As of 6/30/2024)
Stock Exchange: TPO
Fax Number: +886 36581966


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024